Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | ACC| March 29, 2018

Movement Toward Simpler, Wearable Cardiac Monitoring at ACC.18

An example of the new generation of inexpensive, wearable cardiac monitors. This is the Cardea Solo device. #ACC18

An example of the new generation of inexpensive, wearable cardiac monitors that are seeing increased usage. This is the Cardea Solo device. After the monitoring period is over, the wearable patch is torn open to retrieve a data pod that is inserted into a reader to download the data. The software automatically creates reports based on the data, complete with waveforms for various cardiac measures.

The show floor at the American College of Cardiology (ACC) 2018 meeting included numerous vendors offering small, easy-to-use, inexpensive, leadless wearable cardiac monitors. These are being offered as replacements for bulky, expensive Holter monitors that patients wear on their belt and require wire leads to be attached to several points on their bodies. These new monitors can record long periods of cardiac activity and usually have a button for patients to use when they want to flag an event. They can be worn in the shower and while sleeping and offer many practical advantages over the older standard event monitoring technologies. The devices just stick onto a patient's chest and the outer covering is usually disposable. I have seen these devices gaining ground at both ACC and at the 2017 Heart Rhythm Society (HRS) meetings and predict they will be the monitoring technology of choice in the future. 

I spoke with one of these companies, Cardea, which offers the ability for practices to take ownership of their own monitoring services and reports instead of outsourcing it to a third party. I included a segment on how the device works in the VIDEO Editor's Choice of Most Innovative New Cardiac Technology at ACC 2018.

In sessions and one featured research presentation, consumer-grade patient monitoring systems like the Apple Watch were being examined as a way to boost patient engagement and gather long-term data on a patient's cardiac health. One study from Cleveland Clinic showed how a smartwatch could be used to reliably detect atrial fibrillation in patients — ECG on Smartwatch Accurately Detects AFib. It reminded me of one of the key late-breakers from HRS 2017, where Apple Watch heart rate data was used in combination with an artificial intelligence (AI) algorithm to detect atrial fibrillation in patients. That University of California, San Francisco study (Artificial Intelligence Detects AFib Using Apple Watch Heart Rate Sensor) and the new ACC research showed the concept of how consumer devices could be modified to help detect early indicators of cardiac arraythmias long before the owners become symptomatic. It offers food for thought as healthcare looks for new ways to leverage population health data to proactively improve patient outcomes and cut healthcare costs by treating less sick patients. 

 

Key Late-breaking Clinical Trials
I highlighted some of the most interesting late-breaking clinical trials on new technology or new approaches to care presented at ACC in the article Latest Data on Cardiac Technology From ACC.18. It includes key data on greatly improved outcomes of the HeartMate 3 LVAD (left ventricular assist device), wearable defibrillators, six-month dual antiplatelet therapy (DAPT), patent foramen ovale (PFO) closure and a new approach to hypertension patient engagement. 

For a complete list of the late-breakers with links to stories and videos, read the article ACC 2018 Late-Breaking Trials

 

ACC.18 Video Interviews

Here is the list of the nine videos I shot at ACC. The first link is a tour of some of the most interesting new technologies I found on the expo floor.

VIDEO: Editor's Choice of Most Innovative New Cardiac Technology at ACC 2018

VIDEO: Sex Differences in Diagnosing Heart Disease in Women — interview with Doreen DeFaria Yeh, M.D.

VIDEO: TAVR for Degenerated Surgical Valves — Valve-in-Valve TAVR Procedures — interview with Sammy Elmariah, M.D.

VIDEO: iFR Found More Cost Effective Over Standard FFR — interview with Manesh Patel, M.D.

VIDEO: Addressing Adult Congenital Heart Referrals — discussion with Ami Bhatt, M.D.

VIDEO: How to Avoid Acute Kidney Injury in the Cath Lab —  discussion with Hitinder Gurm, M.D.

VIDEO: Therapies for Advanced Heart Failure — interview with David Lanfear M.D.

VIDEO: Detection of Vulnerable Plaque and Pre-emptive Stenting — discussion with Ron Waksman, M.D.

VIDEO: Strategies to Avoid Acute Kidney Injury Caused by Cath Lab Contrast — interview with Roxana Mehran, M.D.

 

#ACC18

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init